摘要： Next-generation sequencing (NGS), also referred to as ‘second-generation sequencing’, ushered in an era of plummeting sequencing costs that has enabled rapid progress in the research of genetic diversity, variants, transcription and epigenetics, among other fields. In the clinical sphere, NGS spurred the dream of precision medicine (PM) or personalized medicine, in which the genome of each patient (or pre-patient) is sequenced, and an optimal treatment is designed based on one’s genetic code, lifestyle and environment. Despite these gains and hopes, NGS is limited by its short-read approach and per-patient cost, and PM has yet to exhibit transformative reach, with only a small proportion of US patients currently receiving genome-informed therapy. In order for PM to become a standard of care, there is an urgent need for fast, cheap and reliable genetic diagnostics to complement existing techniques. We offer a novel high-speed atomic force microscopy ‘nanomapping’ platform to help meet the challenge.